Schedule 13G ownership disclosure

BIODEXA PHARMACEUTICALS PLC SPONSORED

Ordinary Shares, nominal value 0.00005 GBP per share · CUSIP: 59564R807

Event date: 2025-05-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Cavalry Fund I LP

    Shares: 1,460,870,000.00 · Class: 5.7%

  • C/M Capital Partners, LP

    Shares: 1,460,870,000.00 · Class: 5.7%

  • Cavalry Investment Fund LP

    Shares: 74,830,000.00 · Class: 0.3%

  • Cavalry Fund I Management LLC

    Shares: 74,830,000.00 · Class: 0.3%

  • Mercer Street Global Opportunity Fund, LLC

    Shares: 291,520,000.00 · Class: 1.1%

  • Mercer Street Capital Partners, LLC

    Shares: 291,520,000.00 · Class: 1.1%

  • Thomas Walsh

    Shares: 1,535,700,000.00 · Class: 6.0%

  • Jonathan Juchno

    Shares: 1,752,390,000.00 · Class: 6.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-002560
Form type
SCHEDULE 13G
Filer
Biodexa Pharmaceuticals Plc
CIK
CIK 1643918
Filed
May 28, 2025
Reporting period
May 20, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub